Cargando…

Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial

BACKGROUND: Human papillomavirus (HPV) is one of the most significant risk factors for cervical cancer. The HPV vaccine has a very significant impact on the incidence of cervical cancer. The present study aimed to investigate the impact of prophylactic quadrivalent HPV vaccine in the treatment of wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Karimi-Zarchi, Mojgan, Allahqoli, Leila, Nehmati, Ameneh, Kashi, Abolfazl Mehdizadeh, Taghipour-Zahir, Shokouh, Alkatout, Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045378/
https://www.ncbi.nlm.nih.gov/pubmed/32106837
http://dx.doi.org/10.1186/s12889-020-8371-z
_version_ 1783501763450503168
author Karimi-Zarchi, Mojgan
Allahqoli, Leila
Nehmati, Ameneh
Kashi, Abolfazl Mehdizadeh
Taghipour-Zahir, Shokouh
Alkatout, Ibrahim
author_facet Karimi-Zarchi, Mojgan
Allahqoli, Leila
Nehmati, Ameneh
Kashi, Abolfazl Mehdizadeh
Taghipour-Zahir, Shokouh
Alkatout, Ibrahim
author_sort Karimi-Zarchi, Mojgan
collection PubMed
description BACKGROUND: Human papillomavirus (HPV) is one of the most significant risk factors for cervical cancer. The HPV vaccine has a very significant impact on the incidence of cervical cancer. The present study aimed to investigate the impact of prophylactic quadrivalent HPV vaccine in the treatment of women with cervical intraepithelial neoplasia (CIN 1–3). METHODS: This randomized controlled trial was conducted in the Shahid Sadoughi University of Medical Sciences (SSUMS), Yazd, Iran, from October 2011 to November 2015 in women with histologically confirmed residual/recurrent CIN 1 or high-grade CIN (CIN 2–3). Eligible women were assigned randomly to an intervention and a control group. Women in the intervention group were given HPV vaccinations while those in the control group were not. Participants were followed up for 24 months. Primary and secondary outcomes, and adverse effects of the treatment in the two groups were compared using Student’s t test, the chi-square test, or Fisher’s exact test. P values < 0.05 or less were considered statistically significant. RESULTS: Three-hundred and twelve women were randomized to the two groups; the data of 138 in the intervention group and 104 in the control group were analyzed. The mean age of the women was 32.59 ± 4.85 years. Differences in age, marital status, and grades of CIN weren’t significant between the two groups. At the end of the two-year follow-up period, the number of women with CIN 2–3 in the intervention and control groups was reduced by 75% (from 93 to 23) versus 40% (from 69 to 41). The efficacy of the HPV vaccine in women with CIN 1–3 was 58.7% (p = 0.018). No serious adverse effects related to the vaccines were reported. CONCLUSIONS: The prophylactic quadrivalent HPV vaccine after treatment may have a therapeutic effect in women with residual/recurrent CIN 1 or high-grade CIN (CIN 2–3). TRIAL REGISTRATION: Iranian Registry of Clinical Trials, IRCT20190603043801N1. Registered 24 July 2019 – Retrospectively registered, http://www.irct.ir/user/trial/40017/view
format Online
Article
Text
id pubmed-7045378
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70453782020-03-03 Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial Karimi-Zarchi, Mojgan Allahqoli, Leila Nehmati, Ameneh Kashi, Abolfazl Mehdizadeh Taghipour-Zahir, Shokouh Alkatout, Ibrahim BMC Public Health Research Article BACKGROUND: Human papillomavirus (HPV) is one of the most significant risk factors for cervical cancer. The HPV vaccine has a very significant impact on the incidence of cervical cancer. The present study aimed to investigate the impact of prophylactic quadrivalent HPV vaccine in the treatment of women with cervical intraepithelial neoplasia (CIN 1–3). METHODS: This randomized controlled trial was conducted in the Shahid Sadoughi University of Medical Sciences (SSUMS), Yazd, Iran, from October 2011 to November 2015 in women with histologically confirmed residual/recurrent CIN 1 or high-grade CIN (CIN 2–3). Eligible women were assigned randomly to an intervention and a control group. Women in the intervention group were given HPV vaccinations while those in the control group were not. Participants were followed up for 24 months. Primary and secondary outcomes, and adverse effects of the treatment in the two groups were compared using Student’s t test, the chi-square test, or Fisher’s exact test. P values < 0.05 or less were considered statistically significant. RESULTS: Three-hundred and twelve women were randomized to the two groups; the data of 138 in the intervention group and 104 in the control group were analyzed. The mean age of the women was 32.59 ± 4.85 years. Differences in age, marital status, and grades of CIN weren’t significant between the two groups. At the end of the two-year follow-up period, the number of women with CIN 2–3 in the intervention and control groups was reduced by 75% (from 93 to 23) versus 40% (from 69 to 41). The efficacy of the HPV vaccine in women with CIN 1–3 was 58.7% (p = 0.018). No serious adverse effects related to the vaccines were reported. CONCLUSIONS: The prophylactic quadrivalent HPV vaccine after treatment may have a therapeutic effect in women with residual/recurrent CIN 1 or high-grade CIN (CIN 2–3). TRIAL REGISTRATION: Iranian Registry of Clinical Trials, IRCT20190603043801N1. Registered 24 July 2019 – Retrospectively registered, http://www.irct.ir/user/trial/40017/view BioMed Central 2020-02-27 /pmc/articles/PMC7045378/ /pubmed/32106837 http://dx.doi.org/10.1186/s12889-020-8371-z Text en © The Author(s). 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Karimi-Zarchi, Mojgan
Allahqoli, Leila
Nehmati, Ameneh
Kashi, Abolfazl Mehdizadeh
Taghipour-Zahir, Shokouh
Alkatout, Ibrahim
Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial
title Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial
title_full Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial
title_fullStr Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial
title_full_unstemmed Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial
title_short Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial
title_sort can the prophylactic quadrivalent hpv vaccine be used as a therapeutic agent in women with cin? a randomized trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045378/
https://www.ncbi.nlm.nih.gov/pubmed/32106837
http://dx.doi.org/10.1186/s12889-020-8371-z
work_keys_str_mv AT karimizarchimojgan cantheprophylacticquadrivalenthpvvaccinebeusedasatherapeuticagentinwomenwithcinarandomizedtrial
AT allahqolileila cantheprophylacticquadrivalenthpvvaccinebeusedasatherapeuticagentinwomenwithcinarandomizedtrial
AT nehmatiameneh cantheprophylacticquadrivalenthpvvaccinebeusedasatherapeuticagentinwomenwithcinarandomizedtrial
AT kashiabolfazlmehdizadeh cantheprophylacticquadrivalenthpvvaccinebeusedasatherapeuticagentinwomenwithcinarandomizedtrial
AT taghipourzahirshokouh cantheprophylacticquadrivalenthpvvaccinebeusedasatherapeuticagentinwomenwithcinarandomizedtrial
AT alkatoutibrahim cantheprophylacticquadrivalenthpvvaccinebeusedasatherapeuticagentinwomenwithcinarandomizedtrial